GLIDD

DNA Damage Response (DDR) signaling in tumor formation and therapeutic resistance of gliomas

 Coordinatore FUNDACION CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS CARLOS III 

 Organization address address: CALLE MELCHOR FERNANDEZ ALMAGRO 3
city: MADRID
postcode: 28029

contact info
Titolo: Dr.
Nome: Liebanes
Cognome: Dolores
Email: send email
Telefono: +34 912246900
Fax: +34 912246980

 Nazionalità Coordinatore Spain [ES]
 Totale costo 100˙000 €
 EC contributo 100˙000 €
 Programma FP7-PEOPLE
Specific programme "People" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013)
 Code Call FP7-PEOPLE-2013-CIG
 Funding Scheme MC-CIG
 Anno di inizio 2014
 Periodo (anno-mese-giorno) 2014-07-01   -   2018-06-30

 Partecipanti

# participant  country  role  EC contrib. [€] 
1    FUNDACION CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS CARLOS III

 Organization address address: CALLE MELCHOR FERNANDEZ ALMAGRO 3
city: MADRID
postcode: 28029

contact info
Titolo: Dr.
Nome: Liebanes
Cognome: Dolores
Email: send email
Telefono: +34 912246900
Fax: +34 912246980

ES (MADRID) coordinator 100˙000.00

Mappa


 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

modalities    tumors    therapy    tumor    dna    brain    treatment    gbm    patients    resistance    ddr    gliomas    therapeutic    standard   

 Obiettivo del progetto (Objective)

'The gliomas are a large group of brain tumors and Glioblastoma Multiforme (GBM) is the most common and lethal primary central nervous system (CNS) tumor in adults. Despite the recent advances in treatment modalities, GBM patients generally respond poorly to all therapeutic approaches and prognosis remain dismal. Standard therapy for GBMs includes resection of the tumor mass, followed by concurrent radiotherapy and chemotherapy, using the alkylating agent temozolomide (TMZ). Nonetheless, GBM patients remain refractory to treatment. Understanding the genetic events that lead to glioma formation and the mechanisms of resistance to therapy will be instrumental for the development of new treatment modalities for gliomas. Maintenance of genomic integrity is essential for embryonic development and adult tissue homeostasis. Defects in the DNA Damage Response (DDR) machinery, a network of protein complexes capable of detecting DNA lesions and signaling to downstream effector pathways (cell cycle checkpoints, DNA repair, apoptosis, etc.), are linked to numerous pathological states including brain cancers. The focus of this proposal is the identification of DDR genes involved in tumor formation and therapy resistance of gliomas. We will also investigate how the tumor microenvironment contributes to resistance to standard treatment modalities. We reason that these studies will help to define new therapeutic targets for treatment of brain tumors.'

Altri progetti dello stesso programma (FP7-PEOPLE)

SMONDEP (2012)

Scalable Manufacturing of Organic Nano Devices for Electronics and Photonics

Read More  

ENINVEST (2008)

Investments in the electricity market: Model and Applications

Read More  

FLOWMAT (2013)

Exploiting Flow and Capillarity in Materials Assembly: Continuum Modelling and Simulation

Read More